0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover173.64%IV-58.73%PremiumJul 19, 2024Expiry Date0.74Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9492Delta0.3363Gamma1.58Leverage Ratio-0.0017Theta-0.0003Rho-1.50Eff Leverage0.0002Vega
Adaptimmune Therapeutics Stock Discussion
Adaptimmune Therapeutics plc, a company in T-cell therapies, and Galapagos NV, recognized for its innovative approaches to drug discovery and development, have announced a clinical collaboration agreement. This partnership focuses on the exclusive licensing option for Adaptimmune's TCR T-cell therapy candidate, uza-cel, specifical...
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...
No comment yet